Drug intelligence / Profile preview

PR-001

Development stage: Preclinical
Lead developer: Parkure
Modality: Small Molecules
Administration: Intravenous

Overview

PR-001 is a small molecule α-synuclein inhibitor being developed by Parkure for the treatment of Parkinson's disease and other nervous system disorders. Discovered using Parkure's proprietary Drosophila-based phenotypic screening platform, the drug is designed to target synuclein alpha (α-synuclein) to mitigate the protein aggregation and neurotoxicity associated with Parkinson's disease. The development status of PR-001 is currently listed as pending, indicating it is in the early stages of research or awaiting further regulatory classification.

Targets

GBA1 (Glucosylceramidase)

Beyond the preview

Go deeper on PR-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PR-001.

Explore the full profile